Neurocrine Biosciences
NBIX
554 hedge funds and large institutions have $12.5B invested in Neurocrine Biosciences in 2023 Q4 according to their latest regulatory filings, with 94 funds opening new positions, 205 increasing their positions, 200 reducing their positions, and 43 closing their positions.
119% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 43
21% more capital invested
Capital invested by funds: $10.4B → $12.5B (+$2.14B)
18% more call options, than puts
Call options by funds: $64.4M | Put options by funds: $54.6M
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
8% more funds holding
Funds holding: 511 → 554 (+43)
2.59% more ownership
Funds ownership: 93.98% → 96.57% (+2.6%)
3% more repeat investments, than reductions
Existing positions increased: 205 | Existing positions reduced: 200
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$314M |
| 2 |
Dodge & Cox
San Francisco,
California
|
+$120M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$58.8M |
| 4 |
Renaissance Technologies
New York
|
+$45.9M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$137M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$71.9M |
| 3 |
Millennium Management
New York
|
-$66.7M |
| 4 |
Bank of New York Mellon
New York
|
-$64.5M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$43.2M |
NBIX Hedge Fund Activity: Q4 2023 in Review
554 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2023, worth a combined $12.5B — up 21% from $10.4B a quarter earlier.
Buyers outnumbered sellers: 94 funds opened new NBIX positions and 43 closed out — a net gain of 51 holders — while 205 added to existing stakes and 200 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $314M. The largest seller was Point72 Asset Management, cutting an estimated $137M.
- 554 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2023, up from 511 in Q3 2023.
- Funds reported $12.5B of Neurocrine Biosciences stock for Q4 2023, up 21% quarter-over-quarter.
- 94 funds opened new Neurocrine Biosciences positions in Q4 2023 and 43 closed out, a net change of +51 holders.
- The largest Neurocrine Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $314M added.
- The largest Neurocrine Biosciences seller in Q4 2023 was Point72 Asset Management, an estimated $137M sold.
Based on aggregated 13F filings for Q4 2023.